دورية أكاديمية
[Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression].
| العنوان: | [Effects and costs of adjuvant chemotherapy for operable lymph node positive breast cancer with HER2/neu overexpression]. |
|---|---|
| عنوان ترانسليتريتد: | Effecten en kosten van adjuvante chemotherapie bij operabele lymfklierpositieve borstkanker met HER2/neu-overexpressie. |
| المؤلفون: | Vos EJ; Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis, Ples- manlaan 121, 1066 CX, Amsterdam. e.vos@nki.nl, Linn SC, Rodenhuis S |
| المصدر: | Nederlands tijdschrift voor geneeskunde [Ned Tijdschr Geneeskd] 2006 Apr 08; Vol. 150 (14), pp. 776-80. |
| نوع المنشور: | English Abstract; Journal Article; Review |
| اللغة: | Dutch; Flemish |
| بيانات الدورية: | Publisher: Vereniging NTvG Country of Publication: Netherlands NLM ID: 0400770 Publication Model: Print Cited Medium: Print ISSN: 0028-2162 (Print) Linking ISSN: 00282162 NLM ISO Abbreviation: Ned Tijdschr Geneeskd Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017?-: Amsterdam : Vereniging NTvG Original Publication: Houten : Bohn Stafleu van Loghum |
| مواضيع طبية MeSH: | Health Care Costs*, Antibodies, Monoclonal/*therapeutic use , Antineoplastic Agents/*therapeutic use , Breast Neoplasms/*drug therapy , Receptor, ErbB-2/*metabolism, Age Factors ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/economics ; Antibodies, Monoclonal, Humanized ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/economics ; Breast Neoplasms/pathology ; Breast Neoplasms/surgery ; Chemotherapy, Adjuvant/economics ; Cost-Benefit Analysis ; Disease Progression ; Disease-Free Survival ; Female ; Gene Expression Regulation, Neoplastic ; Humans ; Lymphatic Metastasis ; Netherlands ; Prognosis ; Receptor, ErbB-2/blood ; Receptor, ErbB-2/genetics ; Trastuzumab ; Treatment Outcome |
| مستخلص: | Newer forms ofadjuvant chemotherapy can considerably improve the prognosis for breast cancer. The benefits that can be achieved are particularly high for young women (< 50 years) with an unfavourable risk profile (tumour-positive axilliary nodes). The recent application of taxans and trastuzumab has sharply increased the costs of an adjuvant treatment for high-risk mammary breast carcinoma. The cost increase can especially be attributed to trastuzumab. The additional costs of cytostatics (10,079 Euro per life-year gained) appear to be justified if the following is taken into account: women under the age of 50 years still have a life expectancy of approximately 33 years, many have socially relevant positions, and that cure also prevents such things as absence through illness and inability to work as well as expensive palliative care. The pharmaceutical industry spends approximately the same amount on research and innovation as it does on advertising. By reducing marketing costs, there will be more room to lessen the costs of new and socially relevant medications. Ultimately, the pressing question remains on why the Dutch government does not fully compensate hospitals in the Netherlands for the introduction of new, potentially life-saving medications. At present, a substantial percentage of the costs has to be paid by the hospitals themselves out of the regular hospital budget, which is not meant for this. This is happening at the expense of other care to an increasing extent. |
| Number of References: | 19 |
| التعليقات: | Comment in: Ned Tijdschr Geneeskd. 2006 Apr 8;150(14):770-5. (PMID: 16649393) Comment in: Ned Tijdschr Geneeskd. 2006 Jun 24;150(25):1426-7; author reply 1427. (PMID: 16841595) Comment in: Ned Tijdschr Geneeskd. 2006 Jul 1;150(26):1481; author reply 1481-3. (PMID: 16875274) |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Antibodies, Monoclonal, Humanized) 0 (Antineoplastic Agents) EC 2.7.10.1 (Receptor, ErbB-2) P188ANX8CK (Trastuzumab) |
| تواريخ الأحداث: | Date Created: 20060503 Date Completed: 20060525 Latest Revision: 20151119 |
| رمز التحديث: | 20231215 |
| PMID: | 16649394 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 0028-2162 |
|---|